Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535650 | 0.91 | MEP1B (0.48) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7535472 | 0.91 | KMT2A (0.48) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7533758 | 0.91 | MEP1B (0.50) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7533877 | 0.90 | MAPK1 (0.46) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7534707 | 0.88 | MAPK1 (0.70) | MAPK1POLBTSHRKMT2APTGS2 | |
| SCHEMBL7535447 | 0.88 | KMT2A (0.48) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7536227 | 0.87 | KMT2A (0.45) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7536395 | 0.86 | KMT2A (0.47) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7536292 | 0.85 | TUBB1 (0.60) | MAPK1POLBTSHRKMT2AMEP1B | |
| SCHEMBL7535465 | 0.84 | TUBB1 (0.50) | MAPK1POLBTSHRMEP1BTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | AMGEN INC. | 2002-01-31 | — | — | US | claimed |
| EP-1005453-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999010320-A1 | SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS | TULARIK INC. (US) | 1999-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013496-A1 | Benzene compounds as antiproliferative and cholesterol lowering agents | CYP46A1, TGFB1, NR1H2 | MAPK1 263/4885POLB 638/4885TSHR 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.